These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18443033)

  • 21. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers.
    Brand W; van der Wel PA; Rein MJ; Barron D; Williamson G; van Bladeren PJ; Rietjens IM
    Drug Metab Dispos; 2008 Sep; 36(9):1794-802. PubMed ID: 18515333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T; Agarwal S; Elmquist WF
    J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
    Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
    Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry.
    Hou J; Qu F; Wu C; Ren Q; Zhang J
    J Pharm Biomed Anal; 2012 Jul; 66():232-9. PubMed ID: 22472186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
    An G; Gallegos J; Morris ME
    Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
    Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Lee LB; Pang J; Plise EG; Zhang X
    Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
    Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse.
    Zhang Y; Wang H; Unadkat JD; Mao Q
    Drug Metab Dispos; 2007 Dec; 35(12):2154-8. PubMed ID: 17785426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
    Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
    Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
    Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
    Oberoi RK; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.
    Mairinger S; Langer O; Kuntner C; Wanek T; Bankstahl JP; Bankstahl M; Stanek J; Dörner B; Bauer F; Baumgartner C; Löscher W; Erker T; Müller M
    Nucl Med Biol; 2010 Jul; 37(5):637-44. PubMed ID: 20610168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.